{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:48:53Z","timestamp":1782154133146,"version":"3.54.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,24]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Beta-blockers are recommended for post-myocardial infarction (MI) care, but their long-term impact on all-cause mortality in real-world settings remains unclear. This study investigates the association using propensity score methods in a nationally representative cohort, with sensitivity analyses across age subgroups. This retrospective cohort study analyzed data from the National Health and Nutrition Examination Survey, restricted to 2308 MI survivors. Beta-blocker use was the exposure (0: nonuse, 1: use). All-cause mortality, assessed via mortality status (MORTSTAT), was the outcome, with follow-up time measured in person-months from interview (PERMTH_INT). Covariates included age, sex, ethnicity, marital status, poverty-income ratio, education, smoking, alcohol use, and body mass index. Cox proportional hazards regression, propensity score adjustment, matching, and inverse probability of treatment weighting were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Age-stratified sensitivity analyses were conducted for subgroups \u226530, \u226555, \u226560, \u226570, \u226575, and 30\u201380 years to assess the average treatment effect (ATE). Of 2308 participants (mean age 68.7 years, 65% male), 15% used \u03b2-blockers. The crude HR was 0.81 (95% CI: 0.68\u20130.96,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0178). After multivariable adjustment, the HR was 1.03 (95% CI: 0.86\u20131.24,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.7296). Propensity score-matched ATE HR was 0.93 (95% CI: 0.70\u20131.23,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.6029); inverse probability of treatment weighting ATE HR was 1.02 (95% CI: 0.83\u20131.24,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.8786). Weighted Kaplan\u2013Meier estimates showed modest but nonsignificant absolute risk reductions of 1.17% (95% CI: 0.2\u20132.1) at 5 years and 0.81% (95% CI: 0.1\u20131.5) at 10 years, as confidence intervals overlapped substantially with no statistical significance in the differences. Age-stratified analyses showed consistent null effects post-adjustment (e.g., \u226570 years adjusted HR 0.98,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.8992). Subgroup analyses suggested potential benefits in females (HR 0.70,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0290), low-education, and low-income groups, though interactions were nonsignificant. Beta-blocker use was not associated with reduced all-cause mortality in MI survivors after confounder adjustment, with robust findings across age subgroups. These results support personalized therapy approaches rather than routine use. Limitations include potential residual confounding due to the absence of key clinical variables (e.g., left ventricular ejection fraction, revascularization status).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048428","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:03:54Z","timestamp":1777273434000},"page":"e48428","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beta-blocker use and all-cause mortality in myocardial infarction survivors: A retrospective cohort study using propensity score methods in NHANES 1999 to 2018"],"prefix":"10.1097","volume":"105","author":[{"given":"Yingjie","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Cardiology, Jinqiu Hospital of Liaoning Province, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jinqiu Hospital of Liaoning Province, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2362-4889","authenticated-orcid":false,"given":"Ye","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jinqiu Hospital of Liaoning Province, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American heart association.","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines.","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260622","first-page":"4","article-title":"2023 guidelines of the taiwan society of cardiology on the diagnosis and management of chronic coronary syndrome.","volume":"39","author":"Ueng","year":"2023","journal-title":"Acta Cardiol Sin"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"101582","DOI":"10.1016\/j.jacadv.2024.101582","article-title":"Beta-blocker therapy after myocardial infarction.","volume":"4","author":"Cataldo Miranda","year":"2025","journal-title":"JACC Adv"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/heartjnl-2022-322115","article-title":"Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes.","volume":"109","author":"Ishak","year":"2023","journal-title":"Heart"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction.","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction.","volume":"394","author":"Kristensen","year":"2026","journal-title":"N Engl J Med"},{"key":"R10-20260622","first-page":"491","article-title":"Association between \u03b2-blocker dose and quality of life after myocardial infarction: a real-world Swedish register-linked study.","volume":"11","author":"Humphries","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0000000000000741","article-title":"Older adults in the cardiac intensive care unit: factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American heart association.","volume":"141","author":"Damluji","year":"2020","journal-title":"Circulation"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American heart association.","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","article-title":"Association of \u03b2-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis.","volume":"41","author":"Yang","year":"2020","journal-title":"Eur Heart J"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"e003757","DOI":"10.1136\/openhrt-2025-003757","article-title":"Assessment of \u03b2-blocker use and all-cause mortality in patients with myocardial infarction: a real-world analysis of the NHANES 1999-2018 database.","volume":"12","author":"Ling","year":"2025","journal-title":"Open Heart"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"R17-20260622","first-page":"6124559","article-title":"Real-world effectiveness of beta-blockers versus other antihypertensives in reducing all-cause mortality and cardiovascular events.","volume":"2022","author":"Foch","year":"2022"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/pds.5169","article-title":"Incorporating patient generated health data into pharmacoepidemiological research.","volume":"29","author":"Bourke","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"1585067","DOI":"10.3389\/fendo.2025.1585067","article-title":"Correlation of the triglyceride-glucose index with major adverse cardiovascular events in type 2 diabetes mellitus patients with acute myocardial infarction combined with HFpEF.","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R21-20260622","first-page":"1322","article-title":"Missing data in clinical research: a tutorial on multiple imputation.","volume":"37","author":"Austin","year":"2021","journal-title":"Can J Cardiol"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u03b2-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction.","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2307\/2530904","article-title":"Confidence intervals for the survival function using Cox\u2019s proportional-hazard model with covariates.","volume":"40","author":"Link","year":"1984","journal-title":"Biometrics"},{"key":"R24-20260622","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00985768","article-title":"Product-limit survival functions with correlated survival times.","volume":"1","author":"Williams","year":"1995","journal-title":"Lifetime Data Anal"},{"key":"R25-20260622","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/01621459.1952.10483443","article-title":"Confidence intervals for medians and other position measures.","volume":"47","author":"Woodruff","year":"1952","journal-title":"J Am Stat Assoc"},{"key":"R26-20260622","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients.","volume":"11","author":"Na","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R27-20260622","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jtho.2020.12.008","article-title":"Statistical considerations for subgroup analyses.","volume":"16","author":"Wang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R28-20260622","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction.","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"R29-20260622","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ehjcvp\/pvy034","article-title":"Effect of oral \u03b2-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis.","volume":"5","author":"Dahl Aarvik","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R30-20260622","doi-asserted-by":"crossref","first-page":"e010720","DOI":"10.1161\/CIRCINTERVENTIONS.121.010720","article-title":"The art of prescribing \u03b2-blockers after myocardial infarction.","volume":"14","author":"Desta","year":"2021","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:01:51Z","timestamp":1782151311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048428","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"2025-10-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}